

Attorney Docket: UCONAP/141/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Alexandros Makriyannis et al

Application No.: 09/328,742 Examiner: Pryor, Alton Nathaniel

Filing Date: 06/06/1999 Group Art Unit: 1616

For: Inhibitors of the Anandamide Transporter

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Sir:

Information Disclosure Statement

Applicant submits herewith patents, publications or other information of which they are aware and which they believe may be material to the examination of the above-identified application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(b) exists.

Citations in bold type and having a name preceded with *1* indicate references which are believed to be more closely related to the claimed subject matter. This indication is not meant to indicate or imply any position with respect to the remaining references.


Citations in italics and having a name preceded with *** indicate references for which Applicant has no copy to submit. If a copy of any of these references is procured the same will be submitted to the PTO.

Citations having a name preceded with *2* indicate references that were previously cited but for which Applicant had no copy to submit at that time. Copies of these previously cited references are being submitted herewith.


Respectfully submitted,

ALEXANDROS MAKRIYANNIS et al

Date: 1-25-2005
750 Main Street- Suite 1400
Hartford, CT 06103-2721
(860) 527-9211

By: 
James E. Piotrowski
Registration No. 43,860
Alix, Yale & Ristas, LLP
Attorney for Applicants

G:\AYR saved docs\Filing Docs\Uconap\uconap141us\1-05 supp IDS.doc

INFORMATION DISCLOSURE CITATION IN AN APPLICATION 		Application No. 09/328,742	Inventor Alexandros Makriyannis et al		
		Title Inhibitors of the Anandamide Transporter			
		Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US	
UNITED STATES PATENT DOCUMENTS					
Examiner Initial - date	Document No.	Date	Name	Class	
	09/698,071	10/30/00	Fride et al, (copy not included, this is the parent application for US Publication No. 2002/0173528, enclosed herewith)		
	2002/0173528	11/21/02	Fride et al		
	3838131	9/24/74	Gauthier		
	3946029	3/23/76	Descamps et al		
	5631297	5/20/97	*1* Pate et al		
	5939429	8/17/99	Kunos et al		
FOREIGN PATENT DOCUMENTS					
Examiner Initial - date	Document No.	Date	Country	Name	Translation
	EP0444451	9/4/91	EP	Sterling Drug (English bibliography, abstract and cover page, appears equivalent to US5068234 which was previously cited)	
	EP0576357	12/29/93	EP	Barth et al (including English bibliography and abstract)	no
	EP0737671	10/16/96	EP	Takeda Chemical Industries, front page only (bibliography, appears equivalent to US 5804601)	
	IL1995-113228	9/22/99	IL	*1* R. Mechoulam et al (abstract only)	
	WO 02/058636	8/1/02		Makriyannis et al	English
	WO 02/060447	8/8/02		Makriyannis et al	English
	WO 99/57106	11/11/99		Makriyannis et al	English
	WO 97/21682	6/19/97		Barth et al (including bibliography, appears equivalent to US5925768)	no
	WO 94/12466	06/94		*1* Yissum Research Development Co.	English

INFORMATION DISCLOSURE CITATION IN AN OIPE APPLICATION		Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter		
		Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
Examiner Initial - date				
	2 Brotchie JM: Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. (1998)13:871-876. (abstract only)			
	Compton D.R. et al; "Pharmacological Profile Of A Series Of Bicyclic Cannabinoid Analogs: Classification as Cannabimimetic Agents"; J. Pharmacol. Exp. Ther.; 260; 201-209; 1992. (abstract only)			
	2 Dodd, P.R. et al, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981). (abstract only)			
	2 Green K.; "Marijuana smoking vs. cannabinoids for glaucoma therapy."; Arch. Ophthalmol. (1998) Nov. 116(11); 1433-1437. (abstract only)			
	Griffin, G., Wray, E. J., Tao, Q., McAllister, S. D., Rorrer, W. K., Aung, M., Martin, B. R., Abood, M. E.; "Evaluation of the cannabinoid CB2 receptor selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system"; European Journal of Pharmacology; (1999); vol. 377; 117-125.			
	1 Hanus et al; "Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor"; Journal of medicinal Chemistry; 36(20); 3032-3034; 1993			
	Jbilo, O., Derocq, J., Segui, M., Le Fur, G., Casellas, P.; "Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60"; FEBS LETTERS; (1999); vol. 448; no. 21848; 273-277			
	2 Joy JE, Watson SJ, Benson JA; "Marijuana and Medicine Assessing the Science Base"; National Academy Press, Washington, DC, USA (1999). (abstract only)			
	1 Lang, W. et al; "Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase"; J. Med. Chem.; vol. 42(5); 896-902; (1999)			
	1 Lang, W., Qin, C., Hill, W.A., Lin, S., Khanolkar, A.D., Makriyannis, A.; High-Performance Liquid Chromatographic Determination Of Anandamide Amidase Activity in Rat Brain Microsomes; Anal. Biochem; (1996), 238, 40-45 (abstract only)			

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	<p>*2* Maurer-Mehner V, Dittrich A, Hofmann A.; "Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial."; Eur. Arch. Psychiat. Clin. Neurosci. (1990), 240:1-4. (abstract only)</p>		
	<p>*1* Mechoulam et al; Structural Requirements for Binding of Anandamide Type Compounds to the Brain Cannabinoid Receptor; J. Med. Chem.; 1997; 40; 659-667.</p>		
	<p>*1* Mechoulam et al; "Towards Cannabinoid drugs - Revisited"; Progress in Medicinal Chemistry; 35; 199-243; 7/3/1998</p>		
	<p>Meschler, J. P., Kraichely, D. M., Wilken, G. H., Howlett, A. C.; "Inverse Agonist Properties of N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCL (SR141716A) and 1-(2-Chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic Acid Phenylamide (CP-272871) for the CB1 Cannabinoid Receptor"; Biochemical Pharmacology; (2000); vol. 60; no. 9; 1315-1322.</p>		
	<p>Melvin et al; "Structure-Activity Relationships Defining the ACD-Tricyclic Cannabinoids Cannabinoid Receptor Binding and Analgesic Activity"; Drug Design and Discovery; 13(2); 155-166 (1995). (abstract only)</p>		
	<p>*2* Muller-Vahl KB, Kolbe H, Schneider U, Emrich, HM Cannabis in movement disorders. Porsch. Kompimentarmed (1999) 6 (suppl. 3) 23-27. (abstract only)</p>		
	<p>*2* Muller-Vahl KB, Schneider U, Kolbe H, Emrich, HM.; "Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol." Am. J. Psychiat.; (1999); 156(3); 495.</p>		
	<p>Pacheco M, et al; "Aminoalkylindoles: Actions On Specific G-Protein-Linked Receptors"; J. Pharmacol. Exp. Ther.; vol. 257, no. 1, pp. 170-183 and 172 Table (1991).</p>		
	<p>*1* *2* Palmer et al; "Natural and Synthetic Endocannabinoids and Their Structure-Activity Relationships"; Current Pharmaceutical Design; 6; 1381-1397; (2000)</p>		
	<p>*1* Pertwee et al; "Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine"; Br. J. Pharmacol.; 105(4); 980-984 (1992). (abstract only)</p>		
	<p>*1* Pinto et al; Cannabinoid Receptor Binding and Agonist Activity of Amides and Esters of Arachidonic Acid; Mol. Pharmacol.; 1994; 46(3); 516-522. (abstract only)</p>		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
	Title Inhibitors of the Anandamide Transporter		
	Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	1 *2* Porreca F., Mosberg H.I., Hurst R., Hruby V.J., Burks T.F.; "Roles of mu, delta and kappa opiod receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse"; J. Pharmacol. Exp. Ther.; 230(2); 341-348; (1994). (abstract only)		
	Quere, L., Boigegrain, R., Jeanjean, F., Gully, D., Evrard, G., Durant, F.; "Structural requirements of non-peptide neurotensin receptor antagonists"; J. Chem Soc., Perkin Trans. 2, (1996); 2639-2646.		
	1 Razdan et al; "Pharmacological and Behavioral Evaluation of Alkylated Anandamide Analogs"; Life Sci.; 1995; 56(23-24); 2041-2048 (abstract only)		
	2 Rice AS. Cannabinoids and pain. Curr Opin Investig Drugs. 2001 Mar;2(3):399-414. (abstract only)		
	1 *2* Serdarevich B., Caroll K.K., "Synthesis and characterization of 1- and 2-monoglycerides of anteiso fatty acids"; J. Lipid Res.; 7; 277-284; (1966)		
	2 Shen M. Thayer SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol (1996) 54:459-462.		
	1 Sheskin, T. et al; Structural Requirements for Binding of Anandamide Type Compounds to the Brain Cannabinoid Receptor; J. Med. Chem.; 1997; 40; 659-667		
	2 Simiand J, Keane M, Keane PE, Soubrie P: SR 141716, A CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav. Pharmacol (1998) 9:179-181. (abstract only)		
	2 Terranova J-P, Storme J-J Lafon N et al; "Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716"; Psycho-pharmacol (1996) 126:165-172 (abstract only)		
	Tetko, I. V. et al; "Volume Learning Algoritm Artificial Neural Networks For 3D QSAR Studies"; J. Med. Chem.; vol. 44, no. 15 (2001) pp. 2411-2420, 2413, 2414 Table 1.		
	2 Ueda, N., Endocannabinoid hydrolases. Prostaglandins & Other Lipid Mediators 2002;68-69:521-534 (abstract only)		
	2 Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R.; "Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase"; J. Neurochem.; 61(1) 352-355; (1993) (abstract only)		

INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Application No. 09/328,742	Inventor Alexandros Makriyannis et al	
		Title Inhibitors of the Anandamide Transporter		
		Filing Date 06/06/1999	Group Art Unit 1616	Docket No. UCONAP/141/US
	2 Wagner JA, Varga K, Jarai Z, Kunos G; "Mesenteric Vasodilation Mediated by Endothelial Anandamide Receptors"; Hypertension (1999) 33:429-434.			
Examiner		Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.				